The World Health Organization says that its experts have recommended a second malaria vaccine for children, R21/Matrix-M, developed by Britain’s Oxford University.
The R21/Matrix-M vaccine is manufactured by the Serum Institute of India and has already been approved for use in Burkina Faso, Ghana and Nigeria.
“As a malaria researcher, I used to dream of the day we would have a safe and effective vaccine against malaria. Now we have two,” says WHO chief Tedros Adhanom Ghebreyesus.
In 2021, the RTS,S vaccine, produced by British pharmaceutical giant GSK, became the first to be recommended by the WHO to prevent malaria in children in areas with moderate to high malaria transmission.
The WHO’s regional director for Africa, Dr. Matshidiso Moeti, says the new vaccine held great potential for the continent by helping to close the huge demand-and-supply gap.
“Delivered to scale and rolled out widely, the two vaccines can help bolster malaria prevention and control efforts and save hundreds of thousands of young lives in Africa from this deadly disease,” she says.
Is The Times of Israel important to you?
If so, we have a request.
Every day, even during war, our journalists keep you abreast of the most important developments that merit your attention. Millions of people rely on ToI for fast, fair and free coverage of Israel and the Jewish world.
We care about Israel - and we know you do too. So today, we have an ask: show your appreciation for our work by joining The Times of Israel Community, an exclusive group for readers like you who appreciate and financially support our work.
Yes, I'll give
Yes, I'll give
Already a member? Sign in to stop seeing this
You appreciate our journalism
We’re really pleased that you’ve read X Times of Israel articles in the past month.
You clearly find our careful reporting valuable, in a time when facts are often distorted and news coverage often lacks context.
Your support is essential to continue our work. We want to continue delivering the professional journalism you value, even as the demands on our newsroom have grown dramatically since October 7.
So today, please consider joining our reader support group, The Times of Israel Community. For as little as $6 a month you'll become our partners while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
Thank you,
David Horovitz, Founding Editor of The Times of Israel
Join Our Community
Join Our Community
Already a member? Sign in to stop seeing this